Subject: VPH Newsletter - September 2024

In silico trials can streamline the development process of a new drug by using virtual populations based on real patients. This allows to reduce the need for animal and human testing, speed up innovation, and promote early patient access, emphasizing collaboration among various stakeholders.
POLICY NEWS
The EMA is inviting manufacturers of high-risk medical devices and notified bodies to apply for its pilot program to support orphan medical devices. The program provides free advice on a possible orphan device status and on the clinical evaluation of orphan medical devices.
During the summer the MDCG released two important documents: “Guidance on standardisation for medical devices” & “Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation (EU) 2017/746”
The Commission received almost 430 submissions in response to its multi-stakeholder consultation on the upcoming Code of Practice for general-purpose artificial intelligence (GPAI), as provided for by the AI Act.
VPH COMMUNITY
During the last general assembly meeting, the VPHi members approved the creation of an executive committee that will strengthen the interaction between the VPH institute and its membership. The call for nominations is now open with application deadline the 10th of November 2024.



The VPH2024 Conference in Stuttgart has come to a close, and what an incredible four days it has been! With over 400 participants gathered to share cutting-edge research, foster new collaborations, and push the frontiers of in silico medicine, the event has truly confirmed its status as the premier conference in this field.




Among the many wonderful things that happened at VPH2024 we also celebrated the incredible career of one of the in silico medicine pioneers, Marco Viceconti.
Congratulations Marco for all your achievements, and thank you for all you’ve given to this field!




Without data, in silico medicine wouldn't even be possible. In this episode we will explore how data, especially medical data, needs to be managed to make in silico medicine a reality. Our guest for this episode is Elisabetta Biasin, doctoral researcher at the Centre for IT and IP Law at KU Leuven. 

The Virtual Research Environment developed by the SIMCor H2020 Research and Innovation Action for in-silico testing and validation of cardiovascular devices was launched on 4 September 2024 for the benefit of the in-silico medicine community. Access to the platform is open upon registration.
A recent study on Mycobacterium avium complex (MAC) lung disease showcased the potential of virtual trials, predicting how a widely available antibiotic would be a better alternative to the current treatment.
Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter!
YOUNG SCIENTISTS COMMITTEE
23 Oct 2024, Online Registration open!
For VPHi PhD students and postdocs eager to engage in the community Deadline 15 Nov 2024!
New calls with deadlines in October Check them out!
Congratulations to our winner and all the finalists for their contributions! Read blog post
Are you a PhD graduate passionate about in silico medicine? Submit your thesis by 28 Feb 2025!
Check this year's award and don't miss future calls! Read more
VPH EVENTS
14 Oct 2024, Online Registration open
23-24 Oct 2024, Online Registration open
30-31 Oct 2024, Paris - France Registration open
3 Dec 2024, Lisbon - Portugal Paper submission deadline: 15 Oct 2024
7-11 May 2025, Nottingham - UK Challenge submission deadline: 1 Nov 2024
1-5 Jun 2025, Dallas, TX - USA Workshop submission deadline: 1 Oct 2024
ARE YOU NOT A VPHi MEMBER YET? Join us
"The Virtual Physiological Human will revolutionise the way health knowledge is produced stored and managed as well as the way in which healthcare is currently delivered."
 European Commission
LikeTwitterPinterestGooglePlus LinkedInForward
Celestijnenlaan 300C, 3001, Heverlee, Belgium
You may unsubscribe or change your contact details at any time.